

# Fernando Losa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7234378/publications.pdf>

Version: 2024-02-01

19  
papers

222  
citations

1307594

7  
h-index

1125743

13  
g-index

21  
all docs

21  
docs citations

21  
times ranked

379  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. <i>Oncologist</i> , 2021, 26, e769-e779.	3.7	48
2	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. <i>BMC Cancer</i> , 2015, 15, 60.	2.6	41
3	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. <i>Oncologist</i> , 2021, 26, e394-e402.	3.7	39
4	Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0116527.	2.5	34
5	Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. <i>BMC Cancer</i> , 2015, 15, 59.	2.6	20
6	Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. <i>BMC Cancer</i> , 2015, 15, 327.	2.6	13
7	Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3560-3560.	1.6	8
8	SEOMâ€”GECOD clinical guideline for unknown primary cancer (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 681-692.	2.4	7
9	Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24162-e24162.	1.6	6
10	Peripheral Primitive Neuroectodermal Tumor (Ppnet) of Pelvic Origin: Report of a Case Arising from an Unusual Location. <i>Tumori</i> , 2001, 87, 109-111.	1.1	2
11	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3571-3571.	1.6	1
12	Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 501-501.	1.6	1
13	Failure pattern after response to reversible tyrosine kinase inhibitors in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18030-e18030.	1.6	0
14	Prognostic significance of Wnt signaling pathway molecules in nongastric GIST patients: A tissue microarray-based (TMA) analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10529-10529.	1.6	0
15	MicroRNA profiling analysis in a series of high-risk intestinal GISTs.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10532-10532.	1.6	0
16	Correlation of hypertension and proteinuria with outcomes in elderly bevacizumab (BEV)-treated patients with metastatic colorectal cancer (mCRC): Analysis of the BECOX and BECA studies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3589-3589.	1.6	0
17	Induction mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and surgery in high risk rectal cancer: Phase II randomized, multicenter, openlabel trialâ€”The GEMCAD RIA study.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3626-TPS3626.	1.6	0
18	Prognostic relevance of miRNA let-7e in localized intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10524-10524.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Comparison of three molecular methods to detect mutations in <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> and <i>PIK3CA</i> in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3559-3559.	1.6	0